June 7th, 2017

Abiraterone Delays Metastatic Prostate Cancer Growth by 18 Months, Extends Survival

By

Adding Zytiga (abiraterone acetate) plus prednisone to standard hormonal therapy for men with newly diagnosed, metastatic prostate cancer lowers the chance of death by 38%, and more than doubled the median time until the cancer worsened, from 14.8 months to 33 months according to the results of a clinical study featured at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

Current treatment options for prostate cancer include watchful waiting, surgery, chemotherapy, radiation, or hormonal therapy. Hormonal therapy is designed to block testosterone from stimulating the growth of hormone-dependent types of prostate cancer. Some hormonal therapies (such as surgical removal of the testes or use of medications such as leuteinizing hormone releasing hormone [LHRH] analogues) inhibit production of testosterone by the testes. Other therapies, such as the antiandrogen drugs, block the activity of testosterone.

Zytiga is an oral drug that blocks the production of androgens (male hormones such as testosterone) not only by the testes but also by the adrenal glands and is effective in the treatment of advanced hormone refractory prostate cancer.

About the Study

The LATITUDE clinical study treated men with newly diagnosed, high-risk metastatic prostate cancer who had not previously received androgen deprivation therapy (ADT). All patients had at least two of three risk factors: Gleason score (a measure of tumor grade) of 8 or more, 3 or more bone metastases, or 3 or more visceral metastases (spread to other organs in certain areas of the body, such as the liver).  Individuals were treated with ADT plus Zytiga and prednisone, or ADT alone and directly compared.

Results of the clinical study revealed that men who received Zytiga had a 38% lower risk of death, a 53% lower risk of the cancer worsening, and cancer growth was delayed by an average of 18.2 months.
Metastatic prostate cancer has been treated the same way for over 50 years until Taxotere (docetaxel) chemotherapy was shown to improve survival in 2015.  Zytiga may be the next advance in treatment with the potential to further improve outcomes by combining it with Taxotere.  .

Reference:  http://abstracts.asco.org/199/AbstView_199_181729.html

Copyright © 2017 CancerConnect. All Rights Reserved.

Tags: abiraterone, hormone refractory, metastatic prostate cancer, News, Prostate Cancer, Uncategorized, zytiga